BPLPHARMA vs CORONA: Stock Comparison
CORONA REMEDIES is the larger company by market capitalisation. CORONA REMEDIES shows a lower P/E, a higher dividend yield and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BPLPHARMA leads 4; CORONA leads 3 of 9
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Price
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Live Price | ₹1,881.9 | ₹2,441.1 |
| Day Change | 3.46% | 2.58% |
| Volume | 5,812 | 1.45 L |
| 52-Week High | ₹2,295.1 | ₹2,458 |
| 52-Week Low | ₹1,125.7 | ₹1,336.6 |
| Distance from 52W High | -18% | -0.69% |
Valuation
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Market Cap | ₹1,278 Cr | ₹15,290 Cr |
| P/E Ratio | 1,029.83x | 73.86x |
| P/B Ratio | 3.85x | 18.99x |
| EPS | ₹13.66 | ₹9.86 |
| Book Value | ₹452.09 | ₹122.12 |
| Dividend Yield | 0.05% | 0.4% |
Growth
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Revenue Growth (TTM YoY) | 0% | 0% |
| EPS Growth (TTM YoY) | 0% | 0% |
| Qtr Sales Growth | 45.39% | 4.44% |
| Qtr Profit Growth | 431.7% | 0.33% |
Profitability & Leverage
| Metric | BPLPHARMA | CORONA |
|---|---|---|
| ROE | — | 24.78% |
| ROCE | — | 21.44% |
| Net Margin | 0% | 13.19% |
| Operating Margin | — | 17.61% |
| Debt to Equity | — | 0.19x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BPLPHARMA | CORONA |
|---|---|---|
| Promoter Holding | 67.2%▲ 0.03 pp | 69% |
| FII Holding | 0.11% | 4.21%▲ 0.58 pp |
| DII Holding | 1.37%▲ 0.31 pp | 16.45%▲ 3.55 pp |
| Public Holding | 31.31%▼ 0.35 pp | 10.34%▼ 4.14 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BHARAT PARENTERALS and CORONA REMEDIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.